Peter Finlayson

One of my favorite #digitalhealth monthly wrap-ups is from The Heart of Healthcare with Halle Tecco, MPH, MBA and Steve Kraus. In the latest episode 👇, which dropped yesterday, they discuss: -> The Peterson Institute's new report on #digitaltreatments for musculoskeletal conditions (spoiler: this one was much more favorable than their last report on diabetes digital health solutions). (https://lnkd.in/ddk3h-V2) -> The new FDA guidance on diversity in clinical trials, and they touch on a cool initiative that I hadn't heard of from Mural Health aiming to change legislation making clinical trial payments exempt from taxable income. (https://lnkd.in/dtQkpr7Z) -> Goldman Sachs' report that the use of GLP-1 drugs for obesity in the U.S. could result in a whopping 1% increase in GDP. -> Walgreens closing of of a quarter of its stores across the country, raising questions about the sustainability of the traditional pharmacy model in the current market. Lots more in the episode to make this an #interestinglisten for those who are in the #digitalhealth space. 👇 https://lnkd.in/dPWv_57h

26

1 Comment

How do we minimize the number of protocol amendments and increase the operational feasibility of our clinical trials? This article below points out the benefits of using data, conversations and real world data to enhance the feasibility of the protocol design and inclusion/exclusion criteria: 1) Are we being too strict on our criteria in order to "control" for data variability? 2) Do are criteria allow for the intended patient population in the real world (if not, they need to) 3) How realistic is your design in how the study sites actually work? How they see and treat patients? How is your company ensuring the design meets these requirements? https://lnkd.in/gzJzFd-3

4

1 Comment

The intersection of artificial intelligence (AI) and biotechnology holds immense promise for advancing healthcare, from drug discovery and personalized medicine to improving diagnostics and patient care. AI can analyze vast amounts of biological data more quickly and accurately than humans, leading to insights that can accelerate medical breakthroughs. Biotech, on the other hand, provides the tools and techniques to manipulate biological systems, such as gene editing and synthetic biology, which AI can enhance through predictive modeling and optimization. Together, AI and biotech can revolutionize drug development by streamlining the identification of potential drug candidates, predicting their efficacy and safety profiles, and optimizing treatment regimens for individual patients. In diagnostics, AI algorithms can analyze medical images, genetic data, and other biomarkers to improve disease detection and diagnosis accuracy. Additionally, AI-powered wearable devices and remote monitoring systems can provide real-time health insights, enabling early intervention and preventive care. However, this convergence also raises ethical, regulatory, and privacy concerns, particularly regarding the responsible use of patient data, the potential for algorithmic biases, and the implications of gene editing technologies. It's essential for stakeholders in both fields to collaborate closely to ensure that AI-driven biotech innovations prioritize patient safety, equity, and ethical considerations while maximizing their transformative potential in healthcare. #AI #Biotech #drugdevelopment #Data #HIT #predictivemodeling #machinelearning #healthcare #Informatics #ecosystems

6

2 Comments

FDA’s Endorsement: The Marvel of MRD Minimal Residual Disease (MRD) “Elevating MRD to the Forefront” and Revolutionizing Cancer Treatment Approaches The FDA’s Oncologic Drugs Advisory Committee’s recent meeting in April 2024 has cast a spotlight on Minimal Residual Disease (MRD), underscoring its critical role in the advancement of cancer therapies. Here’s how the FDA’s recognition is reshaping the future: 1. Multiple Myeloma: The FDA’s committee has officially recognized MRD as a valid endpoint for accelerated drug approvals. This pivotal decision by the FDA is a testament to MRD’s potential in changing the treatment paradigm for multiple myeloma. 2. Acute Lymphocytic Leukemia (ALL): MRD serves as a vital prognostic indicator, and the FDA’s stance influences treatment choices and regulatory approvals of new medications. It’s a significant step forward, with the FDA’s backing enhancing the credibility of MRD in clinical settings. 3. Chronic Lymphocytic Leukemia (CLL): The MRD status is integral to treatment planning, and the FDA’s consideration is crucial during the approval process of new treatments. The FDA’s involvement ensures that MRD remains a key factor in CLL therapy strategies. 4. Acute Myeloid Leukemia (AML): MRD is being considered by the FDA as a potential surrogate endpoint in trials, which could expedite the approval of innovative AML therapies. The FDA’s support could pave the way for quicker access to new treatments. These examples underscore the vital role of MRD as a clinical endpoint across various cancer types. It’s not just a measure; it’s a movement towards enhancing patient care and fast-tracking the introduction of innovative treatments. The FDA’s Oncologic Drugs Advisory Committee’s discussions and decisions highlight the indispensable role of MRD, now backed by the FDA’s authoritative support. It’s a monumental stride in enhancing patient care and introducing cutting-edge treatments more swiftly, all through the FDA’s visionary lens. For more details, please contact, sales@oliveridleyadvisory.com #oncology #oncolotrials #clinicaltrials #pharma #drugapproval #FDA #minimalresidualdisease #cancer #approval #aacr #esmo #ash Dr. Simone SeiterMoussa Ahmed AmerMou ChatterjeeAnshu Mittal Roy PhD (She/Her)Reena KhuranaKarnik RampalKriti ArnejaMolekule Consulting LLCDavid AldermanAmaninder Singh DhillonVikas SarangalRicha S.Nidhi DhingraYogesh VadepalliBruno LarvolAmit GuptaDr.Hamid Hasan Faridi, MD MBAMichele SpinettaRobert F. Siegmund, PhD MBASabih BeckDr. Timos PapagatsiasSalvador CarlucciDIWAKAR JHA, M.PHARM, M.B.A

3

Thoughts on this? >> FDA questions data on MDMA-based therapy in PTSD ahead of advisory committee >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #healthcare #pharma #biotech

1

Do you feel like you are managing your 340B program all on your own? What if I told you #SUNRx clients enjoy a complete team of #340B experts who work with you to optimize your program to be as compliantly productive as possible? It's true! #SUNRx doesn't just supply you with data, but actually works your program with you. Reach out to me today to learn more!

10

Had to miss today's #BiotechHangout but will be listening on X to make sure that I don't miss the thoughtful discussion and insights shared earlier. I invite you to do the same ICYMI.

8

At present, it is certainly possible to greatly improve the management of sepsis. We need to raise awareness of sepsis as one of the world's leading causes of death; to think about it and recognize it much earlier; and to improve the quality of convalescence. In ICU, intensivists have been working on it practically since the beginning of intensive care in the 60s. Ending sepsis is still a hopeful goal, requiring much more research funding at all levels, from basic science to drugs and markers. What is lacking is a specific treatment, such as antibiotics for bacterial infections or vaccination for viruses, chemotherapy for cancer, therapies for HIV, angioplasty for cardiovascular diseases. All well known diseases compared to sepsis. But what is sepsis? 🔥Sepsis is the body's "desperate" response to an infection it considers threatening. All organs fail to a greater or lesser extent. 🔥Sepsis is often very sudde going from a banal infection to "something else" without realizing it at first. It's an emergency => intensive care (ICU), often life-saving (20-50% mortality). But there is no specific treatment for sepsis. Sepsis is one of the leading causes of mortality, suffering (of families, loved ones, recovering) and healthcare cost worldwide. (20% of global mortality, 0.5% of US GDP). 🔥Furthermore, sepsis let you with long months of recovery and many sequelae are common. https://lnkd.in/eqsKy3_S Sites : https://www.sepsis.org/, https://lnkd.in/etZnq9hh or https://lnkd.in/eRgJyFG8 Tusts like global sepsis alliance https://lnkd.in/ex8Z3sAK , Rory Staunton association https://lnkd.in/ekJxhfxq ; European sepsis alliance https://lnkd.in/eFUimaan ; Sepsis Trust https://lnkd.in/eBF9iWy2, Deutch sepsis Geselchaft https://lnkd.in/eBF9iWy2 France sepsis association https://lnkd.in/ezP_XfBk ; surviving sepsis campaign survivingsepsis.org ….. Review articles in Antiox and Redox Signal - Forceville X, Van Antwerpen P, and Preiser JC https://lnkd.in/epdMBYx5 - Forceville X, Van Antwerpen P, Annane D, and Vincent JL, 2022. https://lnkd.in/dtTivdrv both beta version freely available on pubmed via HAL (select « pubmed » then « Forceville, selenocompounds » and that’s it. #Sepsis = #cancers =#cardiovasculardisease in term of mortality, quality of life suffering and cost #sepsis is an #emmergency such as # infarct #stroke #esicm #sscm #surviving-sepsis #WeAreICU #CriticalCare #IntensiveCare #WorldSepsisDay #SepsisAwareness #ResearchMatters #Healthcare What is ICU https://lnkd.in/e4cfygbx Beginning of ICU (origins) https://lnkd.in/eV46-gxP. Some survivors or relatives from sepsis @Shahrzad Kiavash @Jacqueline Duda @katy Granger @Davy Cotting @Jamila Hedjal @Sandra K and many other. #IntensiveCare #CriticalCare #ICU #Rèanimation #Healthcare #MedicalConference #PatientCare #ClinicalPharmacist #MedicalEducation #ClinicalExcellence #ICUResearch #HealthcareInnovation #CriticalCareNursing #IntensiveCareResearch #PatientSafety

3

Learn the three key takeaways from the Becker's Healthcare CEO + CFO Roundtable discussion on social determinants of health. In the conversation, stakeholders from across the care continuum emphasized the importance of collaboration to scale and implement population health initiatives. Together, we can address social factors that impact care outcomes. #MyCompany #HealthEquity #AmgenSupported

39

The challenge with regulating #PBMs is that the industry is as slippery as it is large. When rebates came under attack, PBMs launched entities that could extract -- and keep -- fees from drugmakers. When biosimilars hit the market, PBMs created subsidiaries to market their own version of the meds, skimming off even more profit.    With every additional middleman inserted into the process, American health care dollars are being squandered and patients suffer.    The New York Times has the receipts.    https://lnkd.in/gMNuaW2y CVS Health's Caremark, United Health's Optum Rx, and Cigna's Express Scripts are destroying the industry while biotech companies are the risk takers and innovators working hard to develop treatments to save lives and greatly improve quality of life. #patientsfirst #innovation #biotech

28

Why are Americans paying so much for #prescription medicines? According to the FTC, it’s because the biggest #PBMs -- all owned by health insurers -- are using their market power to drive up costs, pocket #rebate dollars, and force patients to use pharmacies that the PBMs own. At the same time, they’re providing independent pharmacists with “untenably low” reimbursement, undermining the care ecosystem even as costs increase. The scathing new #PBM report from the FTC makes clear that PBMs are often a shell game, using vertical integration and convoluted corporate structures to hide the fact that PBM "benefits" are often just a way to steer dollars to the PBM's other businesses. Patients suffer the most, first paying higher prices than they should be paying at the pharmacy, and later as they will have access to fewer new treatments because #biotech innovation suffers due to PBM greed, unless we call attention to this egregious behavior. #patientsfirst #innovation #biotech Biotechnology Innovation Organization https://lnkd.in/gK2A2zFh

19

2 Comments

I enjoyed this interview with Re'Onna Vines from Flier Inspired. I was able to give her a bit of context for my answers that I offer here for anyone starting their professional or entrepreneurial journey. 🔹Stay Focused: Keep your goals clear and your priorities straight so you can channel your efforts effectively. 🔹Seek Resources: Always look for knowledge and support to help you tackle challenges and make smart choices. 🔹Ask Questions: Be curious and eager to learn; it’s the best way to understand and gain fresh insights. 🔹Be Bold: Don’t be afraid to step out of your comfort zone. That’s where the real opportunities are. 🔹Take Risks: Embrace smart risks for growth. Even if they don’t always work out, the lessons you learn are invaluable. #artemisfactor #StayFocused #SeekResources #AskQuestions #BeBold #TakeRisks #EntrepreneurAdvice #ProfessionalGrowth #SuccessMindset #CareerTips #Leadership #Innovation #BusinessStrategy

11

2 Comments

I'm so proud to share that I wrote this year's CEO Pay Gap article for BioSpace. We found that despite the strong headwinds that battered the industry last year, CEOs were still often paid hundreds of times more than their median employees. A couple of standouts: 1 - Pfizer head Albert Bourla took a 35% pay cut, but remains one of the highest-paid CEOs across the industry. He takes home nearly 300 times more than the median employee. 2 - J&J CEO Joaquin Duato had the largest pay jump in BioSpace's list, increasing from $13.1 million to $28.4 million. He makes 338 times more than the median J&J employee. 3 - Topping this year's list is Israeli multinational Teva, whose CEO Richard Francis made nearly 400 times more than the median employee. There are more great insights in the article, and I invite you to dive into our analysis. Great work from Jennifer "Jef" Akst, Shawna Williams, and Tyler Patchen, and of course incredible graphics from Nicole Bean and Taylor Tieden. #biotech #biopharma #pharma #PayGap #CEO

11

6 Comments

To continue to the discussions from the American Society of Gene & Cell Therapy conference, check out CTI's Podcast "Moving Medicine Forward," highlighting the work we conduct in Cell and Gene Therapy: 1. Bret Marshall discusses CTI's involvement in Cardiac gene therapy trials, exploring our impact, goals, and industry trends 2. Michael Schmidt and Nicole Sparshott discuss Chain of Custody best practices 3. Joana Lancastre discusses feasibility considerations for Cell and Gene Therapy Trials 4. Jaclyn Guillory shares CTI's experience with enrolling patients to trials with targeted therapies #CTIPodcast #MovingMedicineForward #CRO #ASGCT24 #CellTherapy #GeneTherapy

23

Appreciate John Glasspool’s op/ed in the Boston Business Journal. He brings the perspective of a CEO of a Cambridge-based #biotech, MassBio member Anthos Therapeutics, to the debate over the White House’s plans to use Bayh-Dole as a blunt instrument to force price controls. The reality is that any effort to use “march in” rights like this would hurt innovation, chill the collaborative relationship between research institutes and small biotechs (which are the lion’s share of Massachusetts’ industry) when it comes to advancing early science, and do nothing to address the price of drugs. You can’t argue with Bayh-Dole’s success: 6 million jobs, $2 trillion in economic output, thousands of startups, and 200+ drugs and vaccines. As John points out, we can’t go back to a time when science sat on shelves instead of getting into medicine cabinets. https://lnkd.in/ezkNndKA cc: The Bayh-Dole Coalition

32

3 Comments

I want to remind everyone about the upcoming 2024 Philly Cell & Gene Therapy Conference. Don't miss the "Talk-To-An-Investor" session on June 15th from 2:40 PM to 4:45 PM at the Sheraton Valley Forge Hotel.   This is a fantastic opportunity to engage in 15-minute discussions with esteemed investors if you’re looking for RNA/ASO Tx angled funding.   💡My Session Highlights - June 15th: 1️⃣ Bioanalytical Strategies for In Vivo Quantification of Nucleic Acid Therapy 2️⃣ Delivery Challenges of Oligo Nucleotide Therapy 3️⃣ Model-Informed Drug Development for Nucleic Acid Therapy   At Rockland Immunochemicals, Inc., we're making significant advancements with our ModDetect™ panels. These panels are designed to facilitate the detection of specific chemical modifications independent of the sequence or location of the modification and can be used to evaluate a variety of RNA Tx modalities and nucleic acid structures. We’re collaborating with institutions to continue driving innovation in nucleic acid therapeutics. I would be happy to discuss opportunities with you and help connect you with the right people at the conference.   Looking forward to seeing you there!   #PhillyCGT #CellAndGeneTherapy #RNAtherapy #NucleicAcidTherapy #Biotech #Investors #RocklandImmunochemicals

33